Promatix Biosciences Highlights the Power of its Logic-Gated Proteomics-Driven Bispecific Discovery Platform to Expand the Tumour-Selective ...
Expands potential opportunities for AKTX-101 and its novel RNA splicing modulator payload in additional tumors beyond current ...
Add Yahoo as a preferred source to see more of our stories on Google. Antibody drug conjugates (ADCs) have gained significant momentum in recent years, due to their clinical successes in cancer ...
Just a few years ago, Daniel Chen, M.D., Ph.D., was spending his spare time in his backyard, sketching out designs for new ...
SYNTHBODY(TM) introduces a new class of "smart drugs": protein therapeutics with built-in, multi-layered logic gates that actively change how they behave based on what they encounter in the body, a ...
Dr. Paolo Tarantino shares how antibody-drug conjugates deliver more targeted chemo, and how the treatment lasts longer in the body vs traditional therapy. Antibody-drug conjugates (ADCs) are changing ...
New data highlight predictive patient-derived models, resistance insights, and end-to-end translational workflows to improve translational oncology confidence ...
Sidewinder Therapeutics raises $137M Series B to develop bispecific ADCs for solid tumours and expand clinical pipeline ...
The funding round, led by Novartis and OrbiMed, will allow Sidewinder to progress two of its bispecific ADC programmes to clinical development.
Millions of qubits—rather than the few hundred that are currently possible—are required for quantum computers to achieve their full potential. However, the path toward quantum computer scaling is not ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results